← Back to patent-cliff list
dapagliflozin formate
Tier C — Watch / tradedapagliflozin formate
Dong-A ST Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SGLT2
Indications (approved)：Diabetes, Breast cancer, Type 2 diabetes
Regional status
US
-
EU
Phase II
2023-10-19
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of dapagliflozin formate?
Approved indications include: Diabetes, Breast cancer, Type 2 diabetes.
When does the dapagliflozin formate patent expire?
No public expiry year is available for dapagliflozin formate yet; this page updates once verified.
How do I get a quote for dapagliflozin formate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02